MX2018007392A - Polipeptidos para inhibir la activacion del complemento. - Google Patents
Polipeptidos para inhibir la activacion del complemento.Info
- Publication number
- MX2018007392A MX2018007392A MX2018007392A MX2018007392A MX2018007392A MX 2018007392 A MX2018007392 A MX 2018007392A MX 2018007392 A MX2018007392 A MX 2018007392A MX 2018007392 A MX2018007392 A MX 2018007392A MX 2018007392 A MX2018007392 A MX 2018007392A
- Authority
- MX
- Mexico
- Prior art keywords
- polypeptides
- complement activation
- inhibiting complement
- effector domain
- convertase
- Prior art date
Links
- 230000002401 inhibitory effect Effects 0.000 title abstract 2
- 229920001184 polypeptide Polymers 0.000 title abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 230000024203 complement activation Effects 0.000 title 1
- 239000012636 effector Substances 0.000 abstract 3
- 102000016574 Complement C3-C5 Convertases Human genes 0.000 abstract 2
- 108010067641 Complement C3-C5 Convertases Proteins 0.000 abstract 2
- 230000003831 deregulation Effects 0.000 abstract 1
- 238000006471 dimerization reaction Methods 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Transplantation (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Peptides Or Proteins (AREA)
Abstract
La invención se refiere a un polipéptido que comprende un dominio efector de C3 convertasa, un dominio efector de C5 convertasa y opcionalmente un dominio efector inhibidor del complejo terminal que es resistente a la desregulación por medio de Proteínas FHR fisiológicas y tiene un motivo de dimerización, y a su uso terapéutico.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102015016665 | 2015-12-23 | ||
| PCT/EP2016/082614 WO2017109208A1 (en) | 2015-12-23 | 2016-12-23 | Polypeptides for inhibiting complement activation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018007392A true MX2018007392A (es) | 2018-08-15 |
Family
ID=57838331
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018007392A MX2018007392A (es) | 2015-12-23 | 2016-12-23 | Polipeptidos para inhibir la activacion del complemento. |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US10640540B2 (es) |
| EP (1) | EP3394089B1 (es) |
| JP (2) | JP6771568B2 (es) |
| KR (1) | KR20180091097A (es) |
| CN (1) | CN108699121B (es) |
| AU (1) | AU2016375183B2 (es) |
| BR (1) | BR112018012844A2 (es) |
| CA (1) | CA3009393C (es) |
| DK (1) | DK3394089T3 (es) |
| ES (1) | ES2895256T3 (es) |
| HR (1) | HRP20211608T1 (es) |
| HU (1) | HUE056019T2 (es) |
| IL (1) | IL260182B2 (es) |
| LT (1) | LT3394089T (es) |
| MX (1) | MX2018007392A (es) |
| PL (1) | PL3394089T3 (es) |
| PT (1) | PT3394089T (es) |
| SI (1) | SI3394089T1 (es) |
| WO (1) | WO2017109208A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117338781A (zh) * | 2017-08-31 | 2024-01-05 | 诺华股份有限公司 | 哌啶基-吲哚衍生物的用途 |
| US20200262879A1 (en) | 2017-09-11 | 2020-08-20 | Insideoutbio, Inc. | Methods and compositions to enhance the immunogenicity of tumors |
| US11090304B2 (en) | 2018-05-04 | 2021-08-17 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
| EP3586860A1 (en) * | 2018-06-22 | 2020-01-01 | Universität Ulm | Complement inhibitors and uses thereof |
| DE102018120016B4 (de) * | 2018-08-16 | 2020-09-03 | Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie e.V. -Hans-Knöll-Institut- | Modulatoren der Funktion von Faktor H-verwandtem Protein 1 und deren Verwendungen in der Kontrolle von Entzündung |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0097440B1 (en) * | 1982-06-14 | 1986-09-24 | The Upjohn Company | Method and kit for removing and assaying complement system fragments |
| US5679546A (en) * | 1993-09-24 | 1997-10-21 | Cytomed, Inc. | Chimeric proteins which block complement activation |
| ZA200807620B (en) * | 2006-03-08 | 2009-12-30 | Archemix Corp | Complement binding aptamers and anti-C5 agents useful in the treatment of ocular disorders |
| AR066660A1 (es) * | 2007-05-23 | 2009-09-02 | Genentech Inc | Prevencion y tratamiento de condiciones del ojo asociadas con su complemento |
| CL2008003241A1 (es) | 2007-11-02 | 2009-07-31 | Novartis Ag | Molecula de enlace que comprende una porcion de enlace de antigeno que se enlaza con un neoepitopo de c3b; composicion farmaceutica que la comprende; y su uso para tratar trastornos oculares |
| NZ614351A (en) | 2008-11-10 | 2015-05-29 | Alexion Pharma Inc | Methods and compositions for treating complement-associated disorders |
| JP5740772B2 (ja) * | 2009-08-31 | 2015-07-01 | アイビーシー ファーマスーティカルズ，インコーポレイテッド | 二重特異性免疫サイトカインドック−アンド−ロック（ｄｎｌ）複合体及びその治療的使用 |
| WO2011156356A1 (en) * | 2010-06-09 | 2011-12-15 | Zymogenetics, Inc. | Dimeric vstm3 fusion proteins and related compositions and methods |
| NZ709997A (en) | 2011-04-08 | 2016-03-31 | Univ Leicester | Methods for treating conditions associated with masp-2 dependent complement activation |
| CN102978204B (zh) * | 2011-11-11 | 2018-06-08 | 张康 | Cfhr1基因型、高密度脂蛋白上cfhr1及氧化磷酸胆碱的测定试剂盒及测定方法 |
| WO2013142362A1 (en) * | 2012-03-19 | 2013-09-26 | The Trustees Of The University Of Pennsylvania | Regulator of complement activation and uses thereof |
| FR3015484A1 (fr) * | 2013-12-20 | 2015-06-26 | Lab Francais Du Fractionnement | Proteines recombinantes possedant une activite de facteur h |
| WO2020041644A1 (en) * | 2018-08-22 | 2020-02-27 | Alexion Pharmaceuticals, Inc. | Fusion proteins and methods of treating complement dysregulation using the same |
| GB2583560A (en) * | 2018-12-11 | 2020-11-04 | Admirx Inc | Fusion protein constructs for complement associated disease |
| WO2020232319A1 (en) * | 2019-05-15 | 2020-11-19 | Insideoutbio, Inc. | Modular therapeutics for the treatment of inflammatory diseases and cancer |
| WO2021247487A1 (en) * | 2020-06-01 | 2021-12-09 | Medical University Of South Carolina | Recombinant fusion proteins targeting p-selectin, and methods of use thereof for treating diseases and disorders |
-
2016
- 2016-12-23 MX MX2018007392A patent/MX2018007392A/es unknown
- 2016-12-23 HR HRP20211608TT patent/HRP20211608T1/hr unknown
- 2016-12-23 AU AU2016375183A patent/AU2016375183B2/en active Active
- 2016-12-23 PL PL16828743T patent/PL3394089T3/pl unknown
- 2016-12-23 CA CA3009393A patent/CA3009393C/en active Active
- 2016-12-23 BR BR112018012844A patent/BR112018012844A2/pt active Search and Examination
- 2016-12-23 DK DK16828743.1T patent/DK3394089T3/da active
- 2016-12-23 EP EP16828743.1A patent/EP3394089B1/en active Active
- 2016-12-23 KR KR1020187020929A patent/KR20180091097A/ko not_active Application Discontinuation
- 2016-12-23 CN CN201680075659.0A patent/CN108699121B/zh active Active
- 2016-12-23 HU HUE16828743A patent/HUE056019T2/hu unknown
- 2016-12-23 WO PCT/EP2016/082614 patent/WO2017109208A1/en active Application Filing
- 2016-12-23 LT LTEPPCT/EP2016/082614T patent/LT3394089T/lt unknown
- 2016-12-23 PT PT168287431T patent/PT3394089T/pt unknown
- 2016-12-23 IL IL260182A patent/IL260182B2/en unknown
- 2016-12-23 ES ES16828743T patent/ES2895256T3/es active Active
- 2016-12-23 SI SI201631377T patent/SI3394089T1/sl unknown
- 2016-12-23 US US16/065,272 patent/US10640540B2/en active Active
- 2016-12-23 JP JP2018533148A patent/JP6771568B2/ja active Active
-
2020
- 2020-03-20 US US16/825,711 patent/US11591378B2/en active Active
- 2020-05-01 JP JP2020081070A patent/JP2020167999A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| US20190300589A1 (en) | 2019-10-03 |
| IL260182B2 (en) | 2023-12-01 |
| JP2020167999A (ja) | 2020-10-15 |
| US20200277347A1 (en) | 2020-09-03 |
| CA3009393C (en) | 2023-08-22 |
| ES2895256T3 (es) | 2022-02-18 |
| AU2016375183A1 (en) | 2018-07-19 |
| JP2019508022A (ja) | 2019-03-28 |
| KR20180091097A (ko) | 2018-08-14 |
| DK3394089T3 (da) | 2021-11-01 |
| HRP20211608T1 (hr) | 2022-01-21 |
| LT3394089T (lt) | 2021-11-25 |
| US10640540B2 (en) | 2020-05-05 |
| IL260182A (en) | 2018-07-31 |
| WO2017109208A1 (en) | 2017-06-29 |
| PT3394089T (pt) | 2021-11-03 |
| CA3009393A1 (en) | 2017-06-29 |
| EP3394089A1 (en) | 2018-10-31 |
| SI3394089T1 (sl) | 2021-12-31 |
| BR112018012844A2 (pt) | 2018-12-04 |
| EP3394089B1 (en) | 2021-07-28 |
| AU2016375183B2 (en) | 2021-01-21 |
| CN108699121B (zh) | 2023-07-04 |
| CN108699121A (zh) | 2018-10-23 |
| US11591378B2 (en) | 2023-02-28 |
| HUE056019T2 (hu) | 2022-01-28 |
| PL3394089T3 (pl) | 2022-01-17 |
| JP6771568B2 (ja) | 2020-10-21 |
| IL260182B1 (en) | 2023-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018007392A (es) | Polipeptidos para inhibir la activacion del complemento. | |
| MX2020013881A (es) | Compuestos inhibidores de bcl-xl y conjugados de anticuerpo-farmaco que los incluyen. | |
| IL275333B1 (en) | Inhibitors of fibroblast activation protein | |
| NZ742742A (en) | Compositions and methods for inhibiting arginase activity | |
| PH12016501441A1 (en) | Chimeric alkaline phosphate-like proteins | |
| PH12015501983A1 (en) | Peptides and compositions for treatment of joint damage | |
| MX2019007152A (es) | Peptido novedoso. | |
| EP3645773A4 (en) | THIN KNITWEAR NON-PUMPING, RIP RESISTANT | |
| MA40457A (fr) | Combinaison de médicaments pour traiter le myélome multiple | |
| MX2017011223A (es) | Variantes de protoxina ii y metodos de uso. | |
| IL311678A (en) | A bleeding stop valve is peeling off | |
| PH12017502028A1 (en) | Vortioxetine pyroglutamate | |
| MX2020006510A (es) | Peptido novedoso. | |
| MX2017012654A (es) | Variantes de protoxina-ii y metodos de uso. | |
| EP3111951A4 (en) | Anticancer functional peptide for inhibiting proliferation of cancer stem cell, and use thereof | |
| PH12017500910A1 (en) | Use of sigma receptor ligands in osteoarthritis | |
| GB2560300B (en) | Arc splitter plate | |
| MX2017002277A (es) | Anticuerpos que potencian el factor h y sus usos. | |
| MX2020006758A (es) | Cemento de alumina. | |
| NZ719451A (en) | Glucagon analog for treatment of severe hypoglycemia | |
| MX2017007740A (es) | Peptido c-terminal de acetilcolinesterasa ciclico en el tratamiento o la prevencion de cancer o metastasis. | |
| MA40642A (fr) | Nouveaux dérivés peptidiques et leurs utilisations | |
| MX2017001805A (es) | Combinacion ceramica refractaria asi como producto ceramico refractario. | |
| BR112016007816A2 (pt) | composições peptídicas inovadoras | |
| KR102246870B9 (ko) | 지혈 밸브 장치 |